Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 13/20 | 0.47 |
| ▸ | ACHE | P22303 | 9/20 | 0.47 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583806 | 1.00 | BCHE (0.47) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL16207692 | 1.00 | BCHE (0.47) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL16982822 | 0.92 | BCHE (0.46) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL16982718 | 0.92 | BCHE (0.46) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL16949984 | 0.92 | BCHE (0.46) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL15709627 | 0.80 | BCHE (0.50) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL16207669 | 0.78 | CA12 (0.48) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL16207668 | 0.78 | CA12 (0.48) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL16215647 | 0.78 | CA12 (0.44) | BCHEACHEPTPRFPTPN2PTPN1 | |
| SCHEMBL15709102 | 0.78 | BCHE (0.47) | BCHEACHEPTPRFPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075680-A1 | MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | FUNDACION IMDEA NANOCIENCIA (ES) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075680-A1 | MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | POLR2H, POLRMT, POLR2E | BCHE 3892/4885ACHE 4479/4885PTPRF 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.